Literature DB >> 3491708

In vitro synthesis of IgM rheumatoid factor by lymphocytes from patients with essential mixed cryoglobulinemia.

P L Meroni, W Barcellini, R A Sinico, A Fornasieri, C Sguotti, F Invernizzi, G D'Amico, C Zanussi.   

Abstract

Peripheral blood mononuclear cells (PBMC) from patients with Essential Mixed Cryoglobulinemia (EMC) were studied for their ability to synthesize polyclonal IgM and rheumatoid factor (RF) IgM in vitro. Our results indicate: that EMC-PBMC produce smaller amounts of polyclonal IgM but higher quantities of IgM-RF than normal PBMC after pokeweed mitogen (PWM) or Staphylococcus aureus activation, so that the IgM-RF to total IgM ratio is significantly greater in EMC than in normal cultures; that enriched EMC-B lymphocytes display a significantly higher spontaneous synthesis of IgM-RF than normal B lymphocytes and that the IgM-RF B cell clones are receptive to T cell regulation. Taken together these findings suggest an expansion of B cell clones committed to IgM RF production and the presence in peripheral blood of differentiated B lymphocytes capable of secreting IgM-RF in EMC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491708      PMCID: PMC1542313     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

Review 1.  Pathological expression of idiotypic interactions: immune complexes and cryoglobulins.

Authors:  M Goldman; J C Renversez; P H Lambert
Journal:  Springer Semin Immunopathol       Date:  1983

2.  Defective suppressor cell activity in essential mixed cryoglobulinemia.

Authors:  P L Meroni; W Barcellini; C Messina; G De Bartolo; F Capsoni; F Invernizzi
Journal:  J Clin Lab Immunol       Date:  1982-09

Review 3.  Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system.

Authors:  T A Waldmann; S Broder
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

4.  In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults.

Authors:  W J Koopman; R E Schrohenloher
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

5.  Physiology and pathology of rheumatoid factors.

Authors:  D A Carson; J L Pasquali; C D Tsoukas; S Fong; S F Slovin; S K Lawrance; L Slaughter; J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1981

6.  Regulation of antibody release by naturally occurring anti-immunoglobulins in cultures of pokeweed mitogen-stimulated human peripheral blood lymphocytes.

Authors:  H H Birdsall; R D Rossen
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

7.  Cellular localization of rheumatoid factor idiotypes.

Authors:  V R Bonagura; H G Kunkel; B Pernis
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

8.  Human IgG aggregates induce selective stimulation of IgM rheumatoid factor synthesis by rheumatoid blood mononuclear cells.

Authors:  X L Tao; N Olsen; M Ziff; H E Jasin
Journal:  Arthritis Rheum       Date:  1984-05

9.  Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up.

Authors:  F Invernizzi; M Galli; G Serino; G Monti; P L Meroni; C Granatieri; C Zanussi
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

Review 10.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  2 in total

1.  Clonal B cell expansions in patients with essential mixed cryoglobulinaemia.

Authors:  A Perl; P D Gorevic; D H Ryan; J J Condemi; R J Ruszkowski; G N Abraham
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

2.  Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy.

Authors:  F P Schena; V Scivittaro; E Ranieri; R Sinico; S Benuzzi; M Di Cillo; L Aventaggiato
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.